Bristol-Myers Squibb enters into separate agreements with Biogen and Roche to license anti-etau and anti-myostatin compounds

Bristol-Myers Squibb (BMS) has entered into separate agreements with Biogen and Roche to license anti-etau and anti-myostatin compounds, respectively.

According to Reuters, BMS will receive a combined $470m upfront, along with potential milestone payments and tiered double-digit royalties from each company. 

Under the terms of the agreement to license BMS-986168, Biogen will pay an upfront payment of $300 million to BMS, while Roche will make an upfront payment of $170 million to BMS with potential milestone payments of up to $205 million.